BridgeBio Pharma BBIO is moving from a launch-driven story toward a broader commercial execution test. Attruby has quickly ...

Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage ...

AstraZeneca and Ionis missed a key heart-drug trial goal, shifting attention to BridgeBio’s approved ATTR-CM treatment.

BridgeBio Pharma recently reported multiple developments, including new post-hoc analyses in Circulation: Heart Failure ...

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential ...

The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

"We've had $180.6 million of Attruby sales in U.S. Attruby net product revenue this quarter," CEO Neil Kumar said, adding it was "a 24% growth from the last quarter" and "consistent with the brand ...

To help BridgeBio ramp up for the launch of three new medicines, plus approved ATTR-CM med Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech ...

(RTTNews) - BridgeBio Pharma, Inc. (BBIO), a commercial-stage company, reported narrower net loss for the fourth-quarter, while revenue surged from the prior year on improved product revenue. For the ...

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three ...

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx(R) Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by ...